INTRODUCTION

In the past decade, rates of drug overdose deaths—mainly unintentional overdoses—and suicide have increased in the United States (Hedegaard, Curtin, & Warner, 2020; Hedegaard, Minino, & Warner, 2018; Rudd, Seth, David, & Scholl, 2016). The age-adjusted drug overdose mortality rate increased over 200% between 1999 and 2017 from 6.1 to 21.7 deaths per 100,000 U.S. population, and 87% of the drug overdoses in 2017 were classified as unintentional overdoses (Hedegaard et al., 2018). In the same period, the age-adjusted suicide rate increased 35%, from 10.5 to 14.2 deaths per 100,000 U.S. population.
per 100,000 U.S. population (Hedegaard et al., 2020). The antecedents of unintentional drug overdose death and suicide may be similar even though firearms are the most common mechanism used in suicides (Jack et al., 2018; Sheu, Chen, & Hedegaard, 2015). Both heavily burden a similar demographic group (i.e., adult men of non-Hispanic white race/ethnicity) (CDC WISQARS, 2020; Hedegaard et al., 2020; Rudd et al., 2016; Scholl, Seth, Karisa, Wilson, & Baldwin, 2018) and could occur as maladaptive ways of coping with depression and physical pain (Grattan, Sullivan, Saunders, Campbell, & Von Korff, 2012; Han, Compton, Blanco, & Jones, 2018; Joiner, 2007; Petrosky et al., 2018; Rockett et al., 2014). Nevertheless, these public health problems are largely studied independently. Breaking silos of research to discover shared risk factors for unintentional drug overdose and suicide may inform strategies to prevent these public health problems simultaneously.

Identifying shared risks for fatal drug overdose and suicidal behavior is challenging, because decedents cannot share their precipitating risk exposures. Researchers have examined risk factors, or at least the circumstances of death, among those who died of suicide and other forms of injury through qualitative analyses of death scene investigation reports (e.g., coroner/medical examiner reports or law enforcement reports) (Logan, Ertl, & Bossarte, 2019; Logan, Hall, & Karch, 2011; Logan, Skopp, Karch, Reger, & Ghahm, 2012) or, similarly, through psychological autopsy methods or medical record reviews (Nock et al., 2017). An alternative approach is to study outcomes (e.g., prescription drug misuse and severe suicidal ideation) that pose as key risk factors for the fatal behavior among a living sample. Taking more than prescribed quantities of drugs, particularly opioids, anti-anxiety medications, and sedatives (e.g., benzodiazepines) can increase risk of overdose (Ballantyne, 2012; Jones & McAninch, 2015), or use of drugs commonly involved in overdose deaths such as heroin (Jones, Logan, Gladden, & Bohm, 2015). Similarly, severe levels of suicidal ideation that involve suicidal thoughts, lack of control over thoughts, suicidal impulses, and suicide plans can increase risk of suicidal behavior (Rogers & Joiner, 2018). Examining shared correlates of prescription drug misuse and severe suicidal ideation among a living sample may inform prevention strategies to reduce risk of death. Persons who misuse prescription drugs and attempt suicide often have other comorbid conditions related to pain and/or mental health (Bohnert, Ilgen, Louzon, McCarthy, & Katz, 2017; Garland, Riquino, Priddy, & Bryan, 2017; Han et al., 2018). However, examinations of symptoms associated with conditions such as prior head/neck injury, post-traumatic stress disorder (PTSD), insomnia, and anxiety related to prescription drug misuse and severe suicidal ideation are still needed. These conditions are positively associated with suicide (Bryan & Clemons, 2013; Calabrese et al., 2011; Dobscha et al., 2014; Harnod, Harnod, Lin, Shen, & Kao, 2019; Ribeiro et al., 2012; Vanderploeg et al., 2015; Wisco et al., 2014), and persons with these symptoms are often prescribed drugs such as benzodiazepines (National Institute of Drug Abuse, 2018), which are susceptible to misuse (Blanco, Han, Jones, Johnson, & Compton, 2018).

In addition, there may be avenues to enhance primary prevention efforts. For example, literature on suicide prevention repeatedly shows that enhancing a sense of “belongingness” (i.e., having strong connections to family members, peers, and community) can serve a protective function against suicide (Bryan & Heron, 2015; Bryan, McNaughton-Cassill, & Osman, 2013; Joiner, 2007; Kaminski et al., 2010; Mitchell, Gallaway, Millikan, & Bell, 2012). A sense of belongingness reduces feelings of isolation and gives a sense of confidence that someone will listen when seeking help for mental or emotional distress. Belongingness may also protect against prescription drug misuse. Prior research shows that loneliness can elevate risk of alcohol misuse (Akerlind & Horqust, 1992; Schonfeld, Rohrer, Dupree, & Thomas, 1989) and smoking among adolescents (Seo & Huang, 2012). However, research on whether belongingness is inversely associated with prescription drug misuse needs exploration.

This study examines health-related conditions and belongingness in relation to prescription drug misuse and severe suicidal ideation in a large clinical sample of civilians, Military Service Members, and Veterans at risk for suicide.

2 METHODS

2.1 Data source and population

The Military Suicide Research Consortium’s (MSRC) Common Data Elements (CDE) survey data were used. This survey was developed by the directors of the MSRC and experts from the field of suicide research (Ringer et al., 2018). It was administered to 6555 participants at 26 MSRC-funded research sites evaluating suicide prevention strategies.

For this analysis, we included 10 sites that sampled clinical patients with histories of suicidal ideation and behavior or non-suicidal self-directed violence. Patients were either currently in inpatient or outpatient clinical settings, referred to the study by a provider, or recruited based on recent self-injury or a nonfatal suicide attempt. Depending on the research site, the survey was completed on paper, by interview, online, or using a combination of these approaches, and response rates for these 10 sites ranged from 86% to 100%. Sites that recruited from the general population in community settings were excluded. Also excluded were sites that recruited patients with specific conditions (e.g., anxiety sensitivity and major depressive disorder) that may bias the associations between risk factors ascertained and outcomes. A total sample of 3962 survey participants was included.
Details on patient inclusion/exclusion criteria and survey response rates for the 10 selected MSRC sites are provided online (Table S1). This study examined survey data collected at baseline prior to intervention exposure. Study sites were initiated from 2012 to 2017, distributed nationwide, and included civilians, Military Service Members, and Veterans (Ringer et al., 2018).

MSRC studies were funded through a competitive application process. Military Service Members represented all branches. Institutional Review Board approvals were obtained. Details on the population and MSRC CDEs can be accessed at https://msrc.fsu.edu/members/request-access-msrc-database (Military Suicide Research Consortium).

CDEs are composed of 57 items on participant demographics, suicide-related outcomes (e.g., ideation, plans, attempts), non-suicidal self-directed violent behaviors, and symptoms of psychiatric conditions, prior head/neck injury, substance use, and insomnia. The survey also collected responses on perceived belongingness. Survey questions were either created specifically for this survey (10 items) or drawn from existing, validated measures (47 items) (Ringer et al., 2018). Abbreviated forms of full scales capturing symptoms of the constructs were based on factor loadings from past research and content coverage (Ringer et al., 2018). Brief survey measures were compared to full scales, and all CDE shortened measures were correlated with the corresponding full measures with moderate to strong effect sizes (Ringer et al., 2018).

2.2 Variables

Outcome variables were “any prescription drug misuse” and “severe suicidal ideation.” Any prescription drug misuse was defined as reporting at least some misuse to the question “How often do you use prescription drugs more often or at greater quantities than prescribed?” Responses of some misuse ranged from “monthly or less” to “four or more times per week.” Given this study sample included those at risk of suicidal ideation and behavior, we examined severe suicidal ideation for the second outcome. Severe suicidal ideation was based on four items from the Depressive Symptom Inventory Suicidality Subscale (Metalsky & Joiner, 1997). Items capture within the past two weeks of taking the survey the degree of having thoughts of killing oneself, formulating plans to kill oneself, having little control over suicidal thoughts, and having impulses to kill oneself in response to (some/most/all) situations. For each item, responses were on a scale (0–3) with higher values reflecting greater severity. For each participant, the mean scale score across all items was calculated. Means were divided into equal thirds as closely as possible for the entire MSRC study population.

Those with mean scores closest to the top 33rd percentile of the study population were considered to have high scores on suicidal ideation. Because this study focused on a high-risk clinical subsample of the entire MSRC study population, the proportion of those considered to have high mean scores was skewed to 45.3%. This high score was deemed to be “severe” suicidal ideation for this study, because it equated to (on average) having at least some presence of each of the four suicidal ideation elements (i.e., thoughts, plan formulation, little control over thoughts, and impulsive thoughts) within two weeks of the survey.

Correlates in this study included participant demographic characteristics; symptoms of mental health (MH) factors (i.e., hopelessness, anxiety, and PTSD); frequency and intensity of alcohol use; other substance use (i.e., cocaine, heroin, methamphetamine [meth], marijuana, other pills (i.e., other than those prescribed)); current/recent insomnia symptoms; and prior symptoms of head/neck injury. One protective factor, perceived belongingness, was also examined. Demographic characteristics included age, sex, race/ethnicity, education (highest degree), and military status (i.e., currently serving, Veteran, and never served in the military [a.k.a., “civilians”]). Symptoms of MH factors, other substance use, and other health and relationship factors were provided from established scales (see online material; Table S2). Abbreviated versions of the full scales were only available for our sample, except for survey items capturing other substance use and head/neck injury. Because full scales were not used for some factors, we were precluded from using the official clinical scoring methods and thresholds. Alternatively, mean scores for each factor were calculated for the entire MSRC study population. Based on the distribution of the mean scores, the population was divided roughly into thirds similar to the suicidal ideation outcome variable (i.e., top 33% were considered high scores, middle 33% were considered medium scores, and so forth). This approach was used in other studies (Kaminski et al., 2010; Logan, Crosby, & Hamburger, 2011), and the abbreviated scales used in this study were cross-validated with the full scales (Ringer et al., 2018). Other substance use and prior symptoms of head/neck injury were coded differently. Other substance use was divided into three groups (i.e., never used these drugs, used drugs monthly or less to 2–4 times per month, and used drugs 2 or more times per week). To identify prior symptoms of head/neck injury, the Traumatic Brain Injury-4 (TBI-4) screen was coded according to one of the criterion used by Olson-Madden and colleagues (i.e., [ever/never] where an “ever” status was coded if the respondent answered “yes” to any of the four questions that asked about history of head-/neck-related injuries (Table S2) ( Olson-Madden et al., 2014). This coding approach for the TBI-4 was compared to the Ohio State University TBI-Identification method, a structured interview for identifying lifetime history of TBI; results yielded 74% sensitivity and...
56% specificity (Brenner et al., 2013). Because of the potential for falsely identifying TBI history, this variable was referred to as symptoms of prior head/neck injury. More details on all variable definitions and scale items are provided in the online material (Table S2).

2.3 Analysis

The population was first described with respect to all variables. Poisson regression with robust estimates was used to estimate adjusted prevalence ratios (aPRs) for each outcome, accounting for all variables listed in the tables and clustering at study sites. Two models were tested, one for each outcome. Both models included the same variables with one exception. Prior research showed both outcomes are correlated (Ashrafioun, Bishop, Conner, & Pigeon, 2017; Guo et al., 2016; Schepis, Simoni-Wastila, & McCabe, 2018) so prescription drug misuse was included in the model predicting severe suicidal ideation and vice versa. As a correlate, prescription drug misuse was entered in the model for suicidal ideation as a trinary variable: never (referent); one time per month (or less) to 2–4 times per month; and at least twice per week. Suicidal ideation was also entered into the model for prescription drug misuse as a trinary variable: low mean score (referent); medium mean score; and high or “severe” mean score. We used 97.5% confidence intervals (CIs) to minimize type 1 errors. Regression models only include those with known outcome data. For the model predicting any prescription drug misuse, 3873 respondents (97.8%) had known outcome data and were included; for severe suicidal ideation, 3897 respondents (98.4%) were included. All analyses were conducted with STATA version 12 (College Station, TX).

3 RESULTS

Study sample characteristics are provided in Table 1. Respondents were mostly aged 18–34 years (70.7%), male (61.8%), non-Hispanic white (60.2%), and had at least some college education (61.8%). A high proportion (42.5%) of the sample included Military Service Members, 23.3% were Veterans, 25.6% were civilians, and 8.6% had unknown Military service. Eight-hundred and eighty-six (22.4%) respondents reported current misuse of prescription drugs, with 193 (4.9%) reporting misuse at least twice per week. Further, 1796 (45.3%) respondents had high scores on suicidal ideation (hereafter, “severe suicidal ideation”).

In the adjusted analysis, no individual demographic characteristic was significantly associated with both outcomes (Table 2). Having a medium or higher (vs. low) score of insomnia symptoms was positively associated with prescription drug misuse; a medium (versus low) score of insomnia

| Characteristic | Total Participants (No. (%)) |
|---------------|-----------------------------|
| **Age groups (years)** |                                     |
| 18–34         | 2801 (70.7)                 |
| 35–54         | 749 (18.9)                  |
| 55–74         | 343 (8.7)                   |
| 75+           | 9 (0.2)                     |
| Unknown       | 60 (1.5)                    |
| **Gender**    |                                     |
| Male          | 2447 (61.8)                 |
| Female        | 1384 (34.9)                 |
| Transgender/other | 44 (1.1)           |
| Unknown       | 87 (2.2)                    |
| **Race/Ethnicity** |                                       |
| Non-Hispanic white | 2383 (60.2)            |
| Non-Hispanic black | 496 (12.5)            |
| Non-Hispanic American Indian/Alaskan Native | 35 (0.9) |
| Non-Hispanic Asian/Pacific Islander | 122 (3.1) |
| Non-Hispanic multiracial | 34 (0.9) |
| Other non-Hispanic race | 160 (4.0) |
| Hispanic ethnicity | 399 (10.1) |
| Other ethnicity | 66 (1.7)                    |
| Unknown       | 267 (6.7)                   |
| **Education (highest degree)** |                                                   |
| Less than high school | 150 (3.8)           |
| High school diploma/general equivalency diploma | 1275 (32.2) |
| Some college   | 1784 (45.0)                 |
| College degree | 493 (12.4)                  |
| Beyond college degree | 175 (4.4)          |
| Unknown        | 85 (2.2)                    |
| **Military service** |                                           |
| Currently serving | 1685 (42.5)          |
| Veteran        | 922 (23.3)                  |
| No military service (Civilians) | 1013 (25.6) |
| Unknown        | 342 (8.6)                   |
| **Prescription drug misuse** |                                               |
| Never          | 2987 (75.4)                 |
| One time per month (or less) to four times per month | 693 (17.5) |
| At least twice per week | 193 (4.9)          |
| Unknown        | 89 (2.3)                    |

Suicidal ideation*(Continues)
symptoms was positively associated with severe suicidal ideation (aPR: 1.09; CI: 1.01–1.18). Medium and high scores of perceived belongingness were inversely associated with any prescription drug misuse and severe suicidal ideation (all aPRs \( p < 0.025 \)) (Table 3).

Demographic factors positively associated with any prescription drug misuse included age (35–54 and 55–74 vs. 18–34 years; aPRs \( p < 0.025 \)) and male (vs. female) gender (aPR: 1.12; CI: 1.00–1.24, \( p < 0.025 \)) (Table 2). Compared to civilians, prescription drug misuse was less prevalent among currently serving Military Service Members (aPR: 0.47; CI: 0.38–0.58) and Veterans (aPR: 0.72; CI: 0.58–0.89) (Table 2). Further, prescription drug misuse was positively associated with having a medium and high (versus low) score of PTSD symptoms, a medium and high (vs. low) score of alcohol use, any other substance use (vs. never), and any prior symptoms of head/neck injury (vs. never) (all aPRs \( p < 0.025 \)) (Table 3).

Severe suicidal ideation was less prevalent among those aged 55–74 years versus 18–34 years. Reporting transgender/other (vs. male) gender was positively associated with severe suicidal ideation (aPR: 1.34; CI: 1.12–1.61) (Table 2). Medium and high (vs. low) scores for anxiety symptoms were positively associated with severe suicidal ideation (all \( p < 0.025 \)) (Table 3). Finally, severe suicidal ideation was positively correlated with prescription drug misuse (i.e., one time per month (or less) to 2–4 times per month) (aPR: 1.08; CI: 1.01–1.16) (Table 3).

### 4 | DISCUSSION

This study examined shared health and relationship correlates for prescription drug misuse and severe suicidal ideation among a clinical sample at risk for suicide. Similar to another study (Bohnert et al., 2013), we found anxiety was more directly related to suicidal ideation, while alcohol and other substance use were stronger correlates of prescription drug misuse. Similar findings were reported when histories of those who died of intentional (suicide) overdose were compared to unintentional overdose among nearly 3.3 million Veterans Health Administration patients (Bohnert et al., 2013). MH-related factors were more positively correlated with intentional overdose, and substance use factors were more associated with unintentional overdose (Bohnert et al., 2013).

We also found insomnia symptoms to be positively correlated with both outcomes, even after accounting for symptoms of PTSD, hopelessness, anxiety, prior head/neck injury, and substance use; all factors associated with the outcomes and sleep problems (Al-Ameri, Mohsin, & Abdul Wahid, 2019; Blumenthal, Taylor, Cloutier, Baxley, & Lasslett, 2019; Chakravorty et al., 2013; Hansen et al., 2018). The association between insomnia symptoms and severe suicidal ideation may have occurred because they are both symptoms of depression (American Psychiatric Association, 2013). Insomnia can also be a common side effect of some drug treatments for anxiety and depression, such as selective serotonin-reuptake inhibitors (Argyropoulos & Wilson, 2005; Wichniak, Wierzbicka, Walecka, & Jernajczyk, 2017). Benzodiazepines (e.g., clonazepam) are sometimes prescribed to treat such symptoms or side effects (Minkel & Krystal, 2013). While benzodiazepines are controlled prescription drugs, they are susceptible to misuse (Blanco et al., 2018), which may partially explain the link between insomnia and prescription drug misuse in this study. More work is needed to explore this connection. Based on our findings, insomnia or sleep management strategies such as cognitive behavioral therapy (CBT) should be evaluated on the reduction of insomnia and its potential effects on suicidal ideation and prescription drug misuse (Edinger & Means, 2005; Manber et al., 2011).

Perceived belongingness was inversely associated with both outcomes in this study. Previous research shows that strengthening belongingness can be associated with lowering suicide risk (Bryan & Heron, 2015; Bryan et al., 2013; Kelley et al., 2019), but our finding that belongingness is inversely associated with prescription drug misuse has not been heavily explored and may provide a new direction to proactively prevent prescription drug misuse before it begins. Enhancing belongingness may disrupt some of the forces that drive prescription drug misuse. For example, one theory attributes the causes of the increased rates of opioid overdose and suicide deaths to increased demand for prescription opioids (Bohnert & Ilgen, 2019), and suggest opioid use, like alcohol use, may be a coping device for declining hopefulness about future wealth and opportunities among the working classes (Bohnert & Ilgen, 2019; Case & Deaton, 2015; Dasgupta, Beletsky, & Ciccarone, 2018). Reducing isolation and enhancing connections with others who exhibit healthy prosocial behaviors may replace maladaptive coping devices, improve hopefulness, and strengthen judgment (Center for Substance Abuse Treatment, 1999). Future research is needed to further

### TABLE 1 (Continued)

| Characteristic | Total Participants (No. (%)) |
|---------------|-----------------------------|
| Low score     | 771 (19.5)                  |
| Medium score  | 1330 (33.6)                 |
| High score (Severe) | 1796 (45.3)          |
| Unknown       | 65 (1.6)                    |
| Total         | 3962 (100.0)                |

*Based on four items from the Depressive Symptom Inventory Suicidality Subscale: thoughts of killing oneself, formulating plans to kill oneself, having little control over suicidal thoughts, and having impulses to kill oneself in response to (some/most/all) situations.

| Characteristic | Total Participants (No. (%)) |
|---------------|-----------------------------|
| Unknown       | 65 (1.6)                    |
| Total         | 3962 (100.0)                |

### TABLE 2

| Characteristic | Total Participants (No. (%)) |
|---------------|-----------------------------|
| Low score     | 771 (19.5)                  |
| Medium score  | 1330 (33.6)                 |
| High score (Severe) | 1796 (45.3)          |
| Unknown       | 65 (1.6)                    |
| Total         | 3962 (100.0)                |
develop and test the efficacy of prevention interventions that enhance belongingness on lowering risk of both prescription drug misuse and suicidal ideation.

Table 2: Demographic correlates of prescription drug misuse and severe suicidal ideation: Military Suicide Research Consortium (MSRC) Funded Studies, 2012 to 2017

| Characteristic                          | Any prescription drug misuse | Severe suicidal ideation |
|----------------------------------------|------------------------------|--------------------------|
|                                        | No (%) | Adjusted prevalence ratio (97.5% CI) | No (%) | Adjusted prevalence ratio (97.5% CI) |
| Age groups (years)                     |        |                                     |        |                                     |
| 18–34                                  | 557 (20.2) | Referent | 1275 (46.8) | Referent |
| 35–54                                  | 212 (28.8) | 1.21 (1.15–1.28) | 351 (47.8) | 0.89 (0.79–1.00) |
| 55–74                                  | 100 (30.9) | 1.47 (1.28–1.70) | 137 (41.9) | 0.80 (0.65–0.99) |
| 75+                                    | * (*)   | *                                     | * (*)   | *                                     |
| Gender                                 |        |                                     |        |                                     |
| Male                                   | 469 (19.6) | Referent | 1090 (45.2) | Referent |
| Female                                 | 388 (28.6) | 1.12 (1.00–1.24) | 635 (46.5) | 0.92 (0.81–1.04) |
| Transgender/other                      | 9 (21.4) | 0.91 (0.75–1.09) | 25 (59.5) | 1.34 (1.12–1.61) |
| Race/Ethnicity                         |        |                                     |        |                                     |
| Non-Hispanic white                     | 608 (25.9) | Referent | 1137 (48.3) | Referent |
| Non-Hispanic black                     | 88 (18.1) | 0.77 (0.56–1.05) | 207 (42.1) | 0.88 (0.77–1.01) |
| Non-Hispanic American Indian/Alaskan Native | 10 (29.4) | 1.13 (0.78–1.64) | 16 (45.7) | 0.91 (0.68–1.21) |
| Non-Hispanic Asian/Pacific Islander    | 35 (29.2) | 1.17 (0.96–1.44) | 59 (48.8) | 1.01 (0.92–1.10) |
| Non-Hispanic multiracial               | 10 (29.4) | 0.85 (0.61–1.17) | 22 (64.7) | 1.06 (0.83–1.35) |
| Other Non-Hispanic race                | 30 (19.1) | 0.92 (0.79–1.09) | 65 (41.1) | 0.85 (0.63–1.15) |
| Hispanic ethnicity                     | 63 (16.0) | 0.91 (0.73–1.14) | 164 (41.4) | 0.91 (0.73–1.13) |
| Other ethnicity                        | * (*)   | *                                     | 20 (30.3) | 0.75 (0.43–1.32) |
| Education (highest degree)             |        |                                     |        |                                     |
| Less than high school                  | 35 (24.0) | Referent | 74 (50.3) | Referent |
| High school diploma or equivalency    | 206 (16.5) | 1.18 (0.81–1.72) | 530 (42.0) | 1.00 (0.88–1.13) |
| diploma                                |        |                                     |        |                                     |
| Some college                           | 424 (24.1) | 1.23 (0.83–1.82) | 847 (48.0) | 1.07 (0.95–1.20) |
| College degree                         | 150 (30.8) | 1.34 (0.75–2.38) | 232 (47.5) | 1.04 (0.82–1.32) |
| Beyond college degree                  | 54 (31.4) | 1.54 (0.93–2.54) | 80 (46.5) | 1.15 (0.80–1.66) |
| Military service                       |        |                                     |        |                                     |
| Currently serving                      | 165 (10.0) | 0.47 (0.38–0.58) | 675 (40.3) | 0.95 (0.51–1.74) |
| Veteran                                | 258 (29.2) | 0.72 (0.58–0.89) | 435 (49.0) | 1.08 (0.85–1.38) |
| No military service (civilians)        | 328 (32.9) | Referent | 506 (50.8) | Referent |

*All models adjust for age, gender, race/ethnicity, education, military service, and all other characteristics listed in table 3. Models also accounted for unknown values of each variable; unknown values were not displayed.

Sample is among those with known information on prescription drug misuse (N = 3873).

Sample is among those with known information on suicidal ideation (N = 3897).

* Value suppressed because of low counts.

The positive association between symptoms of head injury and risk of suicide is established (Harnod et al., 2019), and similar to findings on the association of TBI with suicide risk.
| Mental health (MH) factors, Symptoms of: | Any prescription drug misuse | Severe suicidal ideation |
|----------------------------------------|------------------------------|-------------------------|
|                                        | No (%) | Adjusted prevalence ratio (97.5% CI)<sup>a,b</sup> | No (%) | Adjusted prevalence ratio (97.5% CI)<sup>a,c</sup> |
|                                        |        |                                                      |        |                                                      |
| **Suicidal ideation**                  |        |                                                      |        |                                                      |
| Low score                              | 99 (12.9) | Referent                                              |        |                                                      |
| Medium score                           | 296 (22.4) | 1.08 (0.92–1.27)                                       |        |                                                      |
| High score                             | 490 (27.5) | 1.22 (1.01–1.48)                                       |        |                                                      |
| **Hopelessness**                       |        |                                                      |        |                                                      |
| Low score                              | 249 (25.9) | Referent                                              | 394 (40.7) | Referent                                              |
| Medium score                           | 273 (20.5) | 0.94 (0.74–1.20)                                       | 559 (41.9) | 1.08 (0.82–1.41)                                       |
| High score                             | 362 (23.1) | 0.99 (0.82–1.21)                                       | 835 (53.0) | 1.20 (0.84–1.72)                                       |
| **Anxiety**                            |        |                                                      |        |                                                      |
| Low score                              | 231 (17.6) | Referent                                              | 463 (35.1) | Referent                                              |
| Medium score                           | 384 (24.3) | 1.03 (0.96–1.11)                                       | 744 (47.0) | 1.16 (1.02–1.31)                                       |
| High score                             | 270 (27.8) | 1.02 (0.92–1.13)                                       | 585 (60.0) | 1.40 (1.20–1.62)                                       |
| **Post-traumatic stress disorder**     |        |                                                      |        |                                                      |
| Low score                              | 131 (13.0) | Referent                                              | 357 (35.2) | Referent                                              |
| Medium score                           | 322 (23.2) | 1.27 (1.06–1.51)                                       | 619 (44.5) | 1.07 (0.90–1.27)                                       |
| High score                             | 344 (28.8) | 1.30 (1.18–1.43)                                       | 653 (54.5) | 1.15 (0.92–1.43)                                       |
| **Substance use**                      |        |                                                      |        |                                                      |
| Alcohol use                            |        |                                                      |        |                                                      |
| Low score                              | 226 (16.0) | Referent                                              | 644 (44.2) | Referent                                              |
| Medium score                           | 307 (24.5) | 1.34 (1.10–1.63)                                       | 559 (44.5) | 0.98 (0.91–1.04)                                       |
| High score                             | 352 (30.3) | 1.54 (1.33–1.79)                                       | 585 (50.2) | 1.07 (0.99–1.16)                                       |
| Other substance use                    |        |                                                      |        |                                                      |
| Never                                  | 453 (15.6) | Referent                                              | 1272 (43.8) | Referent                                              |
| One time per month (or less) to 2–4 times per month | 194 (42.9) | 1.88 (1.42–2.49)                                       | 230 (50.9) | 0.98 (0.92–1.06)                                       |
| At least twice per week                | 238 (47.0) | 2.08 (1.44–2.99)                                       | 283 (55.8) | 1.06 (0.95–1.19)                                       |
| Prescription drug misuse               |        |                                                      |        |                                                      |
| Never                                  | 1294 (43.4) | Referent                                              | 690 (43.3) | Referent                                              |
| One time per month (or less) to 2–4 times per month | 370 (53.4) | 1.25 (1.09–1.44)                                       | 1098 (48.1) | 1.00 (0.89–1.12)                                       |
| At least twice per week                | 120 (62.5) | 1.19 (1.00–1.43)                                       |        |                                                      |
| Other health factors and perceived belongingness |        |                                                      |        |                                                      |
| Symptoms of prior head/neck injury     |        |                                                      |        |                                                      |
| Never                                  | 283 (17.8) | Referent                                              | 690 (43.3) | Referent                                              |
| Ever                                   | 603 (26.5) | 1.25 (1.09–1.44)                                       | 1098 (48.1) | 1.00 (0.89–1.12)                                       |
| Insomnia Symptoms                      |        |                                                      |        |                                                      |
| Low score                              | 149 (14.8) | Referent                                              | 363 (36.1) | Referent                                              |

(Continues)
(Madsen et al., 2018; Shura et al., 2018; Soberay, Hanson, Dwyer, Plant, & Gutierrez, 2018). However, we did not find a strong association between prior symptoms of head/neck injury and severe suicidal ideation in our adjusted analysis with a clinical sample at high risk for suicide, though these symptoms were positively associated with prescription drug misuse. Research on the relationship of head/neck injury to prescription drug misuse has not received much attention, but positive associations have been reported for TBI, especially among Military Service Members (Golub & Bennett, 2013). Prescription drug misuse among those reporting prior symptoms of head/neck injury may be related to coping with ongoing pain (Irvine & Clark, 2018) and symptoms of depression (Harnod et al., 2019). It may also be related to coping with some secondary symptoms such as difficulties with social interactions, memory, vocational skills, and work performance; these symptoms have been associated with TBI (Lundin, de Boussard, Edman, & Borg, 2006; Tyerman, 2012). In 2013, TBI was diagnosed in almost 2.8 million of the 26 million injury-related emergency department visits, hospitalizations, and deaths in the United States (CDC, 2019), with many survivors living with TBI-related disabilities (Lundin et al., 2006; Tyerman, 2012). Given the frequency of TBIs, and their association with head injuries, monitoring those with histories of TBIs for prescription drug misuse may be worthy of attention (Harnod et al., 2019).

Prescription drug misuse was an independent predictor of severe suicidal ideation in this sample. While this study was unable to examine the specific prescription drugs misused, other studies have found associations between prescription pain medication and suicidal behavior. O’Neill and colleagues (2019) showed a strong link between prescription pain medication and suicide among a population sample in Northern Ireland (O’Neill et al., 2019). Other studies showed higher doses of prescription opioid use are associated with suicide (Han et al., 2018; Ilgen et al., 2016). Ashrafioun and colleagues (2019) also discovered a similar finding that opioid use disorder along with depression or alcohol use disorder increased risk of suicide attempt among 226,444 Military Veterans seeking pain care (Ashrafioun et al., 2019). More research is needed to understand how prescription drug misuse and severe suicidal ideation are linked. At a minimum, prescription drug misuse might be another factor used to help assess suicide risk (Bohnert & Ilgen, 2019).

Our study is subjected to limitations. First, the study was not nationally representative and only included convenience samples of clinical patients at risk of suicide recruited into 10 research studies. If this study was conducted on a sample that reflected the general population, different shared correlates might have emerged. Second, the survey item capturing prescription drug misuse did not collect details on the prescription drugs (e.g., opioids, benzodiazepines, or another type) or whether the increased quantities used were the result of inadvertent nonadherence; such details could have helped characterize the nature of the drug misuse. It also did not incorporate whether drugs were prescribed by multiple providers or obtained illicitly. Only an estimated 35% of those who misuse prescription pain relievers use medications prescribed by one doctor (Substance Abuse & Mental Health Services Administration, 2019). Therefore, this measure most likely underestimated the scope of the prescription drug misuse problem. Relatedly, the “other substance use” variable captured other pill use, which may have involved prescription drug misuse related to drug diversion (i.e., obtaining prescription drugs illegally) and accounted for some of its correlation with prescription drug misuse. Fourth, the survey did not directly collect information on pain, which is a shared risk factor for both suicide (Garland et al., 2017) and prescription drug misuse (Han et al., 2018) as well as sleep problems (Finan, Goodin, & Smith, 2013), which could

### Table 3 (Continued)

| Symptoms of: | Any prescription drug misuse | Severe suicidal ideation |
|-------------|-----------------------------|------------------------|
|             | No (%)                       | Adjusted prevalence ratio (97.5% CI)<sup>a,b</sup> | No (%) | Adjusted prevalence ratio (97.5% CI)<sup>a,c</sup> |
| Medium score | 396 (25.3)                   | 1.39 (1.16–1.66)       | 738 (46.9) | 1.09 (1.01–1.18) |
| High score   | 341 (26.2)                   | 1.42 (1.22–1.65)       | 691 (53.0) | 1.10 (1.00–1.21) |
| Belongingness|                             |                       |          |                 |
| Low score    | 483 (28.3)                   | Referent               | 1000 (58.2) | Referent |
| Medium score | 288 (20.6)                   | 0.87 (0.79–0.97)       | 586 (41.7) | 0.77 (0.68–0.87) |
| High score   | 115 (15.1)                   | 0.86 (0.79–0.94)       | 206 (27.1) | 0.57 (0.45–0.73) |

<sup>a</sup> All models adjust for age, gender, race/ethnicity, education, military service, and all other characteristics listed in table 3. Models also accounted for unknown values of each variable; unknown values were not displayed.

<sup>b</sup> Sample is among those with known information on prescription drug misuse (N = 3873).

<sup>c</sup> Sample is among those with known information on suicidal ideation (N = 3897).
have at least partially explained the positive association identified between sleep problems and the outcomes. Fifth, we were also unable to examine a depression scale with the outcomes, which could also explain the associations between sleep problems and the outcomes. However, sleep problems remained positively associated with the outcomes after adjusting for depression symptoms like hopelessness and anxiety. Sixth, this self-report survey could have been subject to social desirability bias. Last, this study is cross-sectional in design, and therefore, we cannot infer causality in the observed associations.

Strategies that address risk for both prescription drug misuse and severe suicidal ideation may help reduce rising rates of drug overdoses and suicide. This study suggests the potential importance of managing sleep problems and enhancing belongingness as areas to explore for prevention. There are strategies that can enhance connectedness in a community setting that show promise with reducing suicidal behaviors already (Coppens et al., 2014; Kral et al., 2009; WHO, 2018), but more work is needed to evaluate such efforts with respect to reducing prescription drug misuse. Further, more studies are needed to rigorously evaluate therapies for sleep problems on prescription drug misuse and severe suicidal ideation. Future studies should also explore whether there are shared correlates of suicide or drug overdose death using different study methods such as psychological autopsy review, medical chart review, or qualitative analyses of coroner/medical examiner reports and more studies are needed to improve understanding of the causal pathways of our discovered associations.

5 | DISCLAIMERS

None of the authors have a conflict of interest with this manuscript or the research. No financial disclosures were reported by the authors. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The data collection was supported in part by the Military Suicide Research Consortium (MSRC), an effort supported by the Office of the Assistant Secretary of Defense for Health Affairs under Award Nos. (W81XWH-10-2-0181 and W81XWH-10-2-0178). Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the MSRC or the Department of Defense.

ACKNOWLEDGEMENTS

The authors would like to thank Dr. Dennis Reidy for his consultation on the drafting of this manuscript. They would also like to thank the following Principal Investigators (PIs) who provided the data presented in this manuscript: Drs. Courtney Bagge & Ken Conner, PIs of the study, “Warning Signs for Suicide Attempts;” Dr. Sean M. Barnes, PI of the study, “Behaviorally Assessing Suicide Risk;” Dr. Nigel E. Bush, PI of the studies, “Usability and Utility of a Virtual Hope Box (VHB) for Reducing Suicidal Ideation” and “Effectiveness of VHB Smartphone App in Enhancing Veteran’s Coping with Suicidal Ideation;” Dr. Katherine A. Comtois and Thomas E. Joiner, PIs of the study, “Toward a Gold Standard for Suicide Risk Assessment for Military Personnel;” Dr. Lori Johnson, PI of the study, “Suicide Risk Assessments within Suicide-Specific Group Therapy Treatment for Veterans;” Dr. Collin Davidson, PI of the study, “Longitudinal Assessment of Physical Activity and Suicide Risk;” Dr. Jessica Ribeiro, PI of the study, “Short-term Prediction of Suicidal Behavior on a Large Scale;” and Dr. Bridget Matarazzo, PI of the study, “Improving the Inpatient-to-Outpatient Transition.”
Bohnert, A. S., McCarthy, J. F., Ignacio, R. V., Ilgen, M. A., Eisenberg, A., & Blow, F. C. (2013). Misclassification of suicide deaths: Examining the psychiatric history of overdose decedents. *Injury Prevention, 19*(5), 326–330. https://doi.org/10.1136/injur yprev-2012-040631

Bohnert, K. M., Ilgen, M. A., Louzon, S., McCarthy, J. F., & Katz, I. R. (2017). Substance use disorders and the risk of suicide mortality among men and women in the US Veterans Health Administration. *Addiction, 112*(7), 1193–1201. https://doi.org/10.1111/add.13774

Brenner, L. A., Homaiar, B. Y., Olson-Madden, J. H., Nagamoto, H. T., Huggins, J., Schneider, A. L., … Corrigan, J. D. (2013). Prevalence and screening of traumatic brain injury among veterans seeking mental health services. *The Journal of Head Trauma Rehabilitation, 28*(1), 21–30. https://doi.org/10.1097/HTR.0b013e31827df0b5

Bryan, C. J., & Clemans, T. A. (2013). Repetitive traumatic brain injury, psychological symptoms, and suicide risk in a clinical sample of deployed military personnel. *JAMA Psychiatry, 70*(7), 686–691. https://doi.org/10.1001/jamapsychiatry.2013.1093

Bryan, C. J., & Heron, E. A. (2015). Belonging protects against postdeployment depression in military personnel. *Depression and Anxiety, 32*(5), 349–355. https://doi.org/10.1002/daa.22372

Bryan, C. J., McNaughton-Cassil, M., & Osman, A. (2013). Age and belongingness moderate the effects of combat exposure on suicidal ideation among active duty Air Force personnel. *Journal of Affective Disorders, 150*(3), 1226–1229. https://doi.org/10.1016/j.jad.2013.05.087

Calabrese, J. R., Prescott, M., Tamburrino, M., Liberson, I., Slembarski, R., Goldmann, E., … Galea, S. (2011). PTSD comorbidity and suicidal ideation associated with PTSD within the Ohio Army National Guard. *Journal of Clinical Psychiatry, 72*(8), 1072–1078. https://doi.org/10.4088/JCP.11m06956

Case, A., & Deaton, A. (2015). Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century. *Proceedings of the National Academy of Sciences of the United States of America, 112*(49), 15078–15083. https://doi.org/10.1073/pnas.1518393112

CDC. (2020). WISQARS-Web-based injury statistics query and reporting system. Retrieved from https://www.cdc.gov/injury/wisqars/index.html

CDC. (2019). Surveillance Report of Traumatic Brain Injury-related Emergency Department Visits, Hospitalizations, and Deaths—United States, 2014. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Retrieved from https://www.cdc.gov/traumaticbraininjury/pdf/TBI-Surveillance-Report-FINAL_508.pdf

Center for Substance Abuse Treatment. (1999). Enhancing motivation for change in substance abuse treatment. Treatment Improvement Protocol (TIP) Series, No. 35. HHS Publication No. (SMA) 13–4212. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK64967/pdf/Bookshelf_NBK64967.pdf

Chakravorty, S., Grandner, M. A., Kranzer, H. R., Mavandadi, S., Kling, M. A., Perlis, M. L., & Oslin, D. W. (2013). Insomnia in alcohol dependence: Predictors of symptoms in a sample of veterans referred from primary care. *The American Journal of Addictions, 22*(3), 266–270. https://doi.org/10.1111/j.1521-0391.2012.12009.x

Coppens, E., Van Audenhove, C., Iddi, S., Arensman, E., Gottlebe, K., Koburger, N., … Hegerl, U. (2014). Effectiveness of community facilitator training in improving knowledge, attitudes, and confidence in relation to depression and suicidal behavior: Results of the OSPI-Europe intervention in four European countries. *Journal of Affective Disorders, 165*, 142–150. https://doi.org/10.1016/j.jad.2014.04.052

Dasgupta, N., Beletsky, L., & Ciccarone, D. (2018). Opioid crisis: No easy fix to its social and economic determinants. *American Journal of Public Health, 108*(2), 182–186. https://doi.org/10.2105/ajph.2017.304187

Dobscha, S. K., Denneson, L. M., Kovas, A. E., Teo, A., Forsberg, C. W., Kaplan, M. S., … McFarland, B. H. (2014). Correlates of suicide among veterans treated in primary care: Case-control study of a nationally representative sample. *Journal of General Internal Medicine, 29*(Suppl 4), 853–860. https://doi.org/10.1007/s11606-014-3028-1

Edinger, J. D., & Means, M. K. (2005). Cognitive-behavioral therapy for primary insomnia. *Clinical Psychology Review, 25*(5), 539–558. https://doi.org/10.1016/j.cpr.2005.04.003

Finan, P. H., Goodin, B. R., & Smith, M. T. (2013). The association of sleep and pain: An update and a path forward. *The Journal of Pain, 14*(12), 1539–1552. https://doi.org/10.1016/j.jpain.2013.08.007

Garland, E. L., Riquino, M. R., Priddy, S. E., & Bryan, C. J. (2017). Suicidal ideation is associated with individual differences in prescription opioid craving and cue-reactivity among chronic pain patients. *Journal of Addictive Diseases, 36*(1), 23–29. https://doi.org/10.1080/10550887.2016.1220800

Golub, A., & Bennett, A. S. (2013). Prescription opioid initiation, correlates, and consequences among a sample of OEF/ OIF military personnel. *Substance Use & Misuse, 48*(10), 811–820. https://doi. org/10.3109/10826084.2013.796988

Grattan, A., Sullivan, M. D., Saunders, K. W., Campbell, C. I., & Von Korff, M. R. (2012). Depression and prescription opioid misuse among chronic opioid therapy recipients with no history of substance abuse. *The Annals of Family Medicine, 10*(4), 304–311. https://doi.org/10.1370/afm.1371

Guo, L., Xu, Y., Deng, J., Huang, J., Huang, G., Gao, X., … Lu, C. (2016). Association between nonmedical use of prescription drugs and suicidal behavior among adolescents. *JAMA Pediatrics, 170*(10), 971–978. https://doi.org/10.1001/jamapediatrics.2016.1802

Han, B., Compton, W. M., Blanco, C., & Jones, C. M. (2018). Correlates of prescription opioid use, misuse, use disorders, and motivations for misuse among US adults. *Journal of Clinical Psychiatry, 79*(5), 17m11973. https://doi.org/10.4088/JCP.17m11973

Hansen, L. P., Kinskey, C., Koffel, E., Polusny, M., Ferguson, J., Schmer-Galunder, S., & Erbes, C. R. (2018). Sleep patterns and problems among Army National Guard soldiers. *Military Medicine, 183*(11–12), e396–e401. https://doi.org/10.1093/milmed/usy107

Harnod, D., Harnod, T., Lin, C. L., Shen, W. C., & Kao, C. H. (2019). Increased risks of suicide attempt and suicidal drug overdose following admission for head injury in patients with depression. *International Journal of Environmental Research and Public Health, 16*(19), 3524. https://doi.org/10.3390/ijerph16193524

Hedegaard, H., Curtin, S. C., & Warner, M. (2020). Increase in suicide mortality in the United States, 1999–2018: NCHS Data Brief (362). Retrieved from https://www.cdc.gov/nchs/data/databriefs/db362-h.pdf

Hedegaard, H., Minino, A. M., & Warner, M. (2018). Drug Overdose Deaths in the United States, 1999–2017. NCHS Data Brief (329), 1–8. https://www.cdc.gov/nchs/data/databriefs/db329-h.pdf

Ilgen, M. A., Bohnert, A. S., Ganoczy, D., Bair, M. J., McCarthy, J. F., & Blow, F. C. (2016). Opioid dose and risk of suicide. *Pain, 157*(5), 1079–1084. https://doi.org/10.1097/j.pain.0000000000000484
Irvine, K. A., & Clark, J. D. (2018). Chronic pain after traumatic brain injury: Pathophysiology and pain mechanisms. *Pain Medicine, 19*(7), 1315–1333. https://doi.org/10.1093/pm/pnx153

Jack, S. P. D., Petrosky, E., Lyons, B. H., Blair, J. M., Ertl, A. M., Sheats, K. J., & Betz, C. J. (2018). Surveillance for Violent Deaths - National Violent Death Reporting System, 27 States, 2015. *Morbidity and Mortality Weekly Report (Surveillance Summary), 67*(11), 1–32. https://doi.org/10.15585/mmwr.ss6711a1

Joiner, T. (2007). *Why people die by suicide*. Cambridge, MA: USA: Harvard University Press. https://www.hup.harvard.edu/catalog.php?isbn=9780674025493

Jones, C. M., Logan, J., Gladden, R. M., & Bohm, M. K. (2015). Vital signs: Demographic and substance use trends among heroin users -United States, 2002–2013. *Morbidity and Mortality Weekly Report, 64*(26), 719–725.

Jones, C. M., & McAninch, J. K. (2015). Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. *American Journal of Preventive Medicine, 49*(4), 493–501. https://doi.org/10.1016/j.amepre.2015.03.040

Kaminski, J. W., Puddy, R. W., Hall, D. M., Cashman, S. Y., Crosby, A. E., & Ortega, L. A. (2010). The relative influence of different domains of social connectedness on self-directed violence in adolescence. *Journal of Youth and Adolescence, 39*(5), 460–473. https://doi.org/10.1007/s10964-009-9472-2

Kelley, M. L., Bravo, A. J., Davies, R. L., Hamrick, H. C., Vinci, C., & Redman, J. C. (2019). Moral injury and suicidality among combat-wounded veterans: The moderating effects of social connectedness and self-compassion. *Psychological Trauma, 11*(6), 621–629. https://doi.org/10.1037/traa0000447

Kral, M., Wiebe, P. K., Nisbet, K., Dallas, C., Okali, L., Enuaraq, N., & Cinotta, J. (2009). Canadian Inuit community engagement in suicide prevention. *International Journal of Circumpolar Health, 68*(3), 292–308. https://doi.org/10.3402/ijch.v68i3.18330

Logan, J. E., Crosby, A. E., & Hamburger, M. E. (2011). Suicidal ideation, friendships with delinquents, social and parental connectedness, and differential associations by sex: Findings among high-risk pre/early adolescent population. *Crisis, 32*(6), 299–309. https://doi.org/10.1027/0227-5910/a000091

Logan, J. E., Ertl, A., & Bossarte, R. (2019). Correlates of intimate partner homicide among male suicide decedents with known intimate partner problems. *Suicide and Life-Threatening Behavior, 49*(6), 1693–1706. https://doi.org/10.1111/sltb.12567

Logan, J. E., Hall, J., & Karch, D. L. (2011). Suicide categories by patterns of known risk factors: A latent class analysis. *Archives of General Psychiatry, 68*(9), 935–941. https://doi.org/10.1001/archpsyc.2011.85

Logan, J., Skopp, N. A., Karch, D., Reger, M. A., & Gahm, G. A. (2012). Characteristics of suicides among US army active duty personnel in 17 US states from 2005 to 2007. *American Journal of Public Health, 102*(Suppl 1), S40–S44. https://doi.org/10.2105/ajph.2011.300481

Lundin, A., de Boussard, C., Edman, G., & Borg, J. (2006). Symptoms and disability until 3 months after mild TBI. *Brain Injury, 20*(8), 799–806. https://doi.org/10.1080/02699050600744327

Madsen, T., Erlangsen, A., Orlovska, S., Mofaddy, R., Nordentoft, M., & Benros, M. E. (2018). Association between traumatic brain injury and risk of suicide. *Journal of the American Medical Association, 320*(6), 580–588. https://doi.org/10.1001/jama.2018.10211

Manber, R., Bertelt, R. A., Suh, S., Nowakowski, S., Siebern, A. T., & Ong, J. C. (2011). CBT for insomnia in patients with high and low depressive symptom severity: Adherence and clinical outcomes.
suicide risk factors. *Journal of Psychiatric Research,* 98, 78–86. https://doi.org/10.1016/j.jpsychires.2017.12.017

Rudd, R. A., Seth, P., David, F., & Scholl, L. (2016). Increases in drug and opioid-involved overdose deaths - United States, 2010–2015. *Morbidity and Mortality Weekly Report,* 65(5051), 1445–1452. https://doi.org/10.15585/mmwr.mm655051e1

Schepis, T. S., Simoni-Wastila, L., & McCabe, S. E. (2018). Prescription opioid and benzodiazepine misuse is associated with suicidal ideation in older adults. *International Journal of Geriatric Psychiatry,* 34(1), 122–129. https://doi.org/10.1002/gps.4999

Scholl, L., Seth, P., Kariisa, M., Wilson, N., & Baldwin, G. (2018). Drug and opioid-involved overdose deaths - United States, 2013–2017. *Morbidity and Mortality Weekly Report,* 67(5152), 1419–1427. https://doi.org/10.15585/mmwr.mm675152e1

Schonfeld, L., Rohrer, G. E., Dupree, L. W., & Thomas, M. (1989). Antecedents of relapse and recent substance use. *Community Mental Health Journal,* 25(3), 245–249.

Seo, D. C., & Huang, Y. (2012). Systematic review of social network analysis in adolescent cigarette smoking behavior. *Journal of School Health,* 82(1), 21–27. https://doi.org/10.1111/j.1746-1561.2011.00663.x

Sheu, Y., Chen, L., & Hedegaard, H. (2015). Suicide Rates,* by mechanism of injury† — National Vital Statistics System, United States, 1999–2013. *Morbidity and Mortality Weekly Report,* 2015(64), 76.

Shura, R. D., Nazem, S., Miskey, H. M., Hostetter, T. A., Rowland, J. A., Brenner, L. A., … Taber, K. H. (2018). Relationship between traumatic brain injury history and recent suicidal ideation in Iraq/ Afghanistan-era veterans. *Psychological Services,* 16(2), 312–320. https://doi.org/10.1037/ser0000208

Soberay, K. A., Hanson, J. E., Dwyer, M., Plant, E. A., & Gutierrez, P. M. (2018). The relationship between suicidal responses and traumatic brain injury and severe insomnia in active duty, veteran, and civilian populations. *Archives of Suicide Research,* 23(3), 391–410. https://doi.org/10.1080/13811118.2018.1479322

Substance Abuse and Mental Health Services Administration. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54).

Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from https://www.samhsa.gov/data/

Tyerman, A. (2012). Vocational rehabilitation after traumatic brain injury: models and services. *NeuroRehabilitation,* 31(1), 51–62. https://doi.org/10.3233/nre-2012-0774

Vanderploeg, R. D., Nazem, S., Brenner, L. A., Belanger, H. G., Donnell, A. J., & Scott, S. G. (2015). Suicidal ideation among Florida national guard members: Combat deployment and non-deployment risk and protective factors. *Archives of Suicide Research,* 19(4), 453–471. https://doi.org/10.1080/13811118.2014.957454

WHO. (2018). Preventing suicide: A community engagement toolkit. Geneva: World Health Organization; Licence: CC BY-NC-SA 3.0 IGO.

Wichniak, A., Wierzbicka, A., Walecka, M., & Jernajczyk, W. (2017). Effects of antidepressants on sleep. *Current Psychiatry Reports,* 19(9), 63. https://doi.org/10.1007/s11920-017-0816-4

Wisco, B. E., Marx, B. P., Holowka, D. W., Vasterling, J. J., Han, S. C., Chen, M. S., … Keane, T. M. (2014). Traumatic brain injury, PTSD, and current suicidal ideation among Iraq and Afghanistan U.S. veterans. *Journal of Traumatic Stress,* 27(2), 244–248. https://doi.org/10.1002/jts.21900

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.

Tables S1-S2

---

**How to cite this article:** Logan J, Ertl A, Rostad W, Herbst J, Ashby Plant E. Shared correlates of prescription drug misuse and severe suicide ideation among clinical patients at risk for suicide. *Suicide and Life-Threatening Behavior.* 2020;50:1276–1287. https://doi.org/10.1111/sltb.12685